| Literature DB >> 23109850 |
Li Zhang1, Lan Gao1, Zhengjun Li1, Xiaojing Yan1, Yanjing Yang1, Yuping Tang1, Yudan Cao1, Anwei Ding1.
Abstract
The dried roots of Euphorbia kansui (kansui) have been used for centuries in China as a herbal medicine for edema, ascites, and asthma. The 95% ethanol extract showed a significant inhibition of cell proliferation against human normal cell lines L-O2 and GES-1. Bioassay-guided separation of the 95% ethanol extract from the roots of E. kansui led to the isolation of 12 diverse terpenoids whose structures were identified by (1)H, (13)C NMR spectroscopy and ESI-MS as kansuinine A (1), kansuinine B (2), kansuinine C (3), kansuiphorin C (4), 3-O-(2'E,4'Z-decadienoyl)-20-O-acetylingenol (5), 3-O-(2'E,4'Edecadienoyl)-20-O-acetylingenol (6), 3-O-(2'E,4'Z-decadienoyl)-20-deoxyingenol (7), 3-O-benzoyl-20-deoxyingenol (8), 5-O-benzoyl-20-deoxyingenol (9), kansenone (10), epi-kansenone (11), euphol (12). All these 12 terpernoids were evaluated in vitro for cytotoxicity on L-O2 and GES-1 cell lines. Most ingenane-type diterpenoids and 8-ene-7-one triterpenoids (5-11) exhibited a relatively lower IC(50) value; therefore, these compounds had stronger cytotoxicity against human normal cell lines L-O2 and GES-1 with dose-dependent relationships. These results will be significantly helpful to reveal the mechanism of toxicity of kansui and to effectively guide safer clinical application of this herb.Entities:
Keywords: Euphorbia kansui; bio-guided separation; cytotoxicity; human normal gastric epithelial cell line GES-1; human normal liver cell lines L-O2; terpenoids
Mesh:
Substances:
Year: 2012 PMID: 23109850 PMCID: PMC3472742 DOI: 10.3390/ijms130911247
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 6.208
The proliferation inhibition activities of kansui extract and compounds 1–12 on human normal liver cells L-O2 and gastric epithelial cell GES-1 (n = 6).
| Extract/Compounds | IC50 | |
|---|---|---|
|
| ||
| L-O2 | GES-1 | |
| EtOH extract | 42.02 μg/mL | 30.67 μg/mL |
| EtOAc extract | 27.08 μg/mL | 21.89 μg/mL |
| Water extract | >100 μg/mL | >100 μg/mL |
| 1 | >100 μM | >100 μM |
| 2 | >100 μM | >100 μM |
| 3 | >100 μM | >100 μM |
| 4 | >100 μM | >100 μM |
| 5 | 12.40 μM | 8.51 μM |
| 6 | 8.22 μM | 6.67 μM |
| 7 | 13.08 μM | 3.53 μM |
| 8 | 70.78 μM | 23.51 μM |
| 9 | 34.53 μM | 22.01 μM |
| 10 | 14.36 μM | 13.44 μM |
| 11 | 17.82 μM | 8.04 μM |
| 12 | >100 μM | >100 μM |
Figure 1The chemical structures of compounds 1–12.
The 1H-NMR spectral assignments (δ/ppm) for compounds 1–3 in CDCl3 (300 MHz).
| Position | 1 | Position | 2 | 3 |
|---|---|---|---|---|
| 1 | 2.66 (dd, 6.3, 14.1) | 1 | 4.33 (brs) | 4.94 (s) |
| 2.25 (m) | ||||
| 2 | 2.10 (m) | 2 | - | - |
| 3 | 5.60 (brs) | 3 | 5.53 (d, 4.8) | 5.38 (d, 4.7) |
| 4 | 2.98 (brs) | 4 | 3.63 (dd, 11.4, 5.0) | 3.48 (m) |
| 5 | 6.15 (s) | 5 | 5.93 (d, 5.85) | 5.95 (s) |
| 7 | 6.44 (s) | 7 | 5.88 (s) | 5.88(s) |
| 8 | 6.05 (s) | 8 | 4.66 (brs) | 4.70 (d, 9.3) |
| 9 | 5.09 (s) | 9 | - | - |
| 11 | 4.14 (s) | 11 | 3.70 (d, 1.8) | 3.65 (d, 2.04) |
| 12 | - | 12 | 3.33 (m) | 3.46 (m) |
| 13 | 2.33 (q, 6.6) | 13 | 3.38 (m) | 3.26 (m) |
| 16 | 0.936 (d, 6.6) | 16 | 1.29 (s) | 1.32 (s) |
| 17 | 5.24 (s) | 17 | 6.52 (s) | 6.390 (s) |
| 5.14 (s) | 5.94 (s) | 5.95 (s) | ||
| 18 | 1.31 (s) | 18 | 1.35 (s) | 1.33 (s) |
| 19 | 1.15 (s) | 19 | 0.85 (s) | 0.89 (s) |
| 20 | 1.32 (d, 6.3) | 20 | 1.53 (d, 6.27) | 1.65 (d, 6.51) |
| Acetyls | - | Acetyls | - | - |
| COMe-1 | - | COMe-1 | - | 2.14 (s) |
| COMe-3 | 2.10 (s) | COMe-3 | 1.90 (s) | 1.95 (s) |
| COMe-5 | 2.08 (s) | COMe-5 | - | - |
| COMe-7 | 2.19 (s) | COMe-7 | - | - |
| COMe-9 | 2.01 (s) | COMe-9 | - | - |
| COMe-15 | 1.96 (s) | COMe-15 | 2.32 (s) | - |
| Benzoyls | - | Benzoyls | - | - |
| COPh-8 -2,6 | 8.05 (m) | COPh-5-2,6 | 7.56 (m) | 7.48 (m) |
| -3,5 | 7.44 (m) | -3,5 | 7.03 (m) | 6.88 (m) |
| -4 | 7.55 (m) | -4 | 7.22 (m) | 7.06 (m) |
| COPh-7-2,6 | - | COPh-7-2,6 | 7.51 (m) | 7.53 (m) |
| -3,5 | - | -3,5 | 6.93 (m) | 7.02 (m) |
| -4 | - | -4 | 7.10 (m) | 7.25 (m) |
| OH-1 | - | OH-1 | 3.94 (brs) | - |
| OH-2 | - | OH-2 | 2.53 (m) | 2.33 (s) |
| OH-8 | - | OH-8 | 3.59 (m) | 3.50 (m) |
| OH-15 | - | OH-15 | - | 4.10 (s) |
The 1H-NMR spectral assignments (δ/ppm) for compounds 4–9 in CDCl3 (300 MHz).
| Position | 4 | 5 | 6 | 7 | 8 | 9 |
|---|---|---|---|---|---|---|
| 1 | 6.14 (brs) | 6.05 (s) | 6.04 (s) | 6.07 (s) | 6.14 (s) | 6.02 (s) |
| 3 | 5.07 (s) | 5.60 (s) | 5.57 (s) | 5.53 (s) | 5.67 (s) | 3.73 (s) |
| 5 | 5.51 (brs) | 3.88 (s) | 3.88 (s) | 3.68 (s) | 3.76 (brs) | 5.41 (s) |
| 7 | 5.88 (d, 1.5) | 6.12 (d, 3.7) | 6.12 (d, 3.7) | 5.76 (m) | 5.78 (m) | 5.91 (m) |
| 8 | 4.26 (dd, 9.5, 1.5) | 4.08 (dd, 4.0, 11.7) | 4.08 (dd, 4.0, 11.7) | 4.02 (dd, 9.9, 3.0) | 4.03 (m) | 4.13 (dd, 7.0, 14.2) |
| 11 | 2.31 (m) | 2.49 (m) | 2.48 (m) | 2.46 (m) | 2.54 (m) | 2.41 (m) |
| 12 | 2.54 (m) | 2.26 (m) | 2.26 (m) | 2.26 (m) | 2.28 (m) | 2.34 (m) 1.77 |
| 1.73 (m) | 1.75 (m) | 1.76 (m) | 1.74 (m) | 1.75 (m) | (m) | |
| 13 | 0.74 (m) | 0.72 (m) | 0.72 (m) | 0.67 (m) | 0.67 (m) | 0.70 (m) |
| 14 | 0.88 (m) | 0.98 (m) | 0.98 (m) | 0.90 (m) | 0.93 (m) | 0.94 (m) |
| 16 | 1.07 (s) | 1.06 (s) | 1.06 (s) | 1.05 (s) | 1.04 (s) | 1.07 (s) |
| 17 | 1.13 (s) | 1.08 (s) | 1.08 (s) | 1.08 (s) | 1.06 (s) | 1.17 (s) |
| 18 | 1.00 (d, 4.7) | 1.00 (d, 7.3) | 1.00 (d, 7.3) | 0.99 (d, 7.2) | 1.05 (d, 4.2) | 0.98 (d, 5.61) |
| 19 | 1.78 (brs) | 1.8 (d, 1.1) | 1.8 d (1.1) | 1.80 (brs) | 1.83 (d, 1.5) | 1.83 (s) |
| 20 | 1.56 (s) | 4.75, 4.49 (Abq, 12.5) | 4.75, 4.49 (Abq, 12.5) | 1.79 (s) | 1.81 (s) | 1.60 (s) |
| 3-R, 2′ | 8.13 (m) | 5.95 (d, 15.3) | 5.86 (d, 15.3) | 5.95 (d, 5.1) | 8.04 (d, 7.3) | - |
| 3′ | 7.48 (m) | 7.70 (m) | 7.31 (m) | 7.68 (dd, 15.3, 11.4) | 7.48 (t, 7.6) | - |
| 4′ | 7.60 (m) | 6.16 (m) | 6.21 (m) | 6.16 (m) | 7.61 (t, 7.3) | - |
| 5′ | - | 5.95 (m) | 6.21 (m) | 5.94 (m) | - | - |
| 6′ | - | 2.29 (m) | 2.20 (m) | 2.34 (m) | - | - |
| 7′ | - | 1.43 (m) | 1.43 (m) | 1.43 (m) | - | - |
| 8′ | - | 1.31 (m) | 1.31 (m) | 1.29 (m) | - | - |
| 9′ | - | 1.28 (m) | 1.28 (m) | - | - | |
| 10′ | - | 0.89 (t, 7.0) | 0.72 (t, 7.0) | 0.89 (m) | - | - |
| OAc | - | 2.06 (s) | 2.05 (s) | - | - | - |
| 5-R, 2′ | 2.05 (s) | - | - | - | - | 8.10 (m) |
| 3′ | - | - | - | - | - | 7.46 (m) |
| 4′ | - | - | - | - | - | 7.60 (m) |
The 1H-NMR spectral assignments (δ/ppm) for compounds 10 and 11 in CDCl3 (300 MHz).
| Position | 10 | 11 |
|---|---|---|
| 1α | 1.44 (m) | 1.44 (m) |
| 1β | 1.86 (m) | 1.86 (m) |
| 2 | 1.76 (m) | 1.75 (m) |
| 1.67 (m) | 1.66 (m) | |
| 3α | 3.29 (dd, 4.6,11.6) | 3.29 (dd, 4.6,11.6) |
| 5α | 1.67 (m) | 1.66 (m) |
| 6α | 2.40 (m) | 2.41 (m) |
| 6β | 2.38 (m) | 2.38 (m) |
| 11α | 2.37 (m) | 2.36 (m) |
| 11β | 2.24 (m) | 2.24 (m) |
| 12α | 1.76–1.80 (m) | 1.76–1.80 (m) |
| 15α | 1.55 (m) | 1.55 (m) |
| 15β | 2.12 (m) | 2.12 (m) |
| 16α | 1.34 (m) | 1.34 (m) |
| 16β | 1.93 (m) | 1.94 (m) |
| 17 | 1.44 (m) | 1.46 (m) |
| 18 | 0.73 (s) | 0.73 (s) |
| 19 | 1.06 (s) | 1.05 (s) |
| 20 | 1.41 (m) | 1.43 (m) |
| 21 | 0.88 (d, 6.0) | 0.93 (d, 6.1) |
| 22 | 1.13 (m), 1.55 (m) | 1.05 (m), 1.48 (m) |
| 23 | 1.90 (m), 2.04 (m) | 1.82 (m), 2.04 (m) |
| 24 | 5.09 (m) | 5.10 (m) |
| 26 | 1.69 (s) | 1.68 (s) |
| 27 | 1.61 (s) | 1.60 (s) |
| 28 | 0.99 (s) | 0.99 (s) |
| 29 | 0.88 (s) | 0.88 (s) |
| 30 | 0.97 (s) | 0.96 (s) |
Figure 2The cytotoxicity and dose-dependent relationship of compounds 5–11 on human normal cell lines GES-1.
Figure 3The cytotoxicity and dose-dependent relationship of compounds 5–11 on human normal cell lines L-O2.